Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 139 entries
Sorted by: Best Match Show Resources per page
Nutritional Risk in Major Abdominal Surgery: Protocol of a Prospective Observational Trial to Evaluate the Prognostic Value of Different Nutritional Scores in Pancreatic Surgery.

JMIR research protocols

Probst P, Haller S, Dörr-Harim C, Bruckner T, Ulrich A, Hackert T, Diener MK, Knebel P.
PMID: 26573991
JMIR Res Protoc. 2015 Nov 16;4(4):e132. doi: 10.2196/resprot.4567.

BACKGROUND: The influence of patients' preoperative nutritional status on their clinical outcome has already been proven. Therefore, patients with malnutrition are in need of additional therapeutic efforts. However, for pancreatic surgery, evidence suggesting the adequacy of existing nutritional assessment...

Cite
Probst P, Haller S, Dörr-Harim C, et al. Nutritional Risk in Major Abdominal Surgery: Protocol of a Prospective Observational Trial to Evaluate the Prognostic Value of Different Nutritional Scores in Pancreatic Surgery. JMIR Res Protoc. 2015;4(4):e132doi: 10.2196/resprot.4567.
Probst, P., Haller, S., Dörr-Harim, C., Bruckner, T., Ulrich, A., Hackert, T., Diener, M. K., & Knebel, P. (2015). Nutritional Risk in Major Abdominal Surgery: Protocol of a Prospective Observational Trial to Evaluate the Prognostic Value of Different Nutritional Scores in Pancreatic Surgery. JMIR research protocols, 4(4), e132. https://doi.org/10.2196/resprot.4567
Probst, Pascal, et al. "Nutritional Risk in Major Abdominal Surgery: Protocol of a Prospective Observational Trial to Evaluate the Prognostic Value of Different Nutritional Scores in Pancreatic Surgery." JMIR research protocols vol. 4,4 (2015): e132. doi: https://doi.org/10.2196/resprot.4567
Probst P, Haller S, Dörr-Harim C, Bruckner T, Ulrich A, Hackert T, Diener MK, Knebel P. Nutritional Risk in Major Abdominal Surgery: Protocol of a Prospective Observational Trial to Evaluate the Prognostic Value of Different Nutritional Scores in Pancreatic Surgery. JMIR Res Protoc. 2015 Nov 16;4(4):e132. doi: 10.2196/resprot.4567. PMID: 26573991; PMCID: PMC4704883.
Copy Download .nbib Format: NLM
Intrapulmonal dislocation of a totally implantable venous access device.

World journal of surgical oncology

Hackert T, Tjaden C, Kraft A, Sido B, Dienemann H, Buchler MW.
PMID: 15823210
World J Surg Oncol. 2005 Apr 11;3(1):19. doi: 10.1186/1477-7819-3-19.

BACKGROUND: Totally implantable venous access devices are widely used for infusion of chemotherapy or parenteral nutrition. Device associated complications include technical operative problems, infections, paravasal infusions and catheter or punction chamber dislocation. CASE PRESENTATION: We present the case of...

Cite
Hackert T, Tjaden C, Kraft A, et al. Intrapulmonal dislocation of a totally implantable venous access device. World J Surg Oncol. 2005;3(1):19doi: 10.1186/1477-7819-3-19.
Hackert, T., Tjaden, C., Kraft, A., Sido, B., Dienemann, H., & Buchler, M. W. (2005). Intrapulmonal dislocation of a totally implantable venous access device. World journal of surgical oncology, 3(1), 19. https://doi.org/10.1186/1477-7819-3-19
Hackert, Thilo, et al. "Intrapulmonal dislocation of a totally implantable venous access device." World journal of surgical oncology vol. 3,1 (2005): 19. doi: https://doi.org/10.1186/1477-7819-3-19
Hackert T, Tjaden C, Kraft A, Sido B, Dienemann H, Buchler MW. Intrapulmonal dislocation of a totally implantable venous access device. World J Surg Oncol. 2005 Apr 11;3(1):19. doi: 10.1186/1477-7819-3-19. PMID: 15823210; PMCID: PMC1087895.
Copy Download .nbib Format: NLM
Symptoms and surgical management of a distal choledochal cyst in a patient with pancreas divisum: case report and review of the literature.

Case reports in gastroenterology

Hackert T, Hartwig W, Werner J.
PMID: 21487552
Case Rep Gastroenterol. 2007 Oct 02;1(1):90-5. doi: 10.1159/000108636.

We report the case of a 63-year-old woman who presented with the rare finding of a distal choledochocele in a pancreas divisum with recurrent abdominal pain and episodes of pancreatitis. She underwent successful resection with choledochectomy, papillectomy and reconstruction...

Cite
Hackert T, Hartwig W, Werner J. Symptoms and surgical management of a distal choledochal cyst in a patient with pancreas divisum: case report and review of the literature. Case Rep Gastroenterol. 2007;1(1):90-5doi: 10.1159/000108636.
Hackert, T., Hartwig, W., & Werner, J. (2007). Symptoms and surgical management of a distal choledochal cyst in a patient with pancreas divisum: case report and review of the literature. Case reports in gastroenterology, 1(1), 90-5. https://doi.org/10.1159/000108636
Hackert, Thilo, et al. "Symptoms and surgical management of a distal choledochal cyst in a patient with pancreas divisum: case report and review of the literature." Case reports in gastroenterology vol. 1,1 (2007): 90-5. doi: https://doi.org/10.1159/000108636
Hackert T, Hartwig W, Werner J. Symptoms and surgical management of a distal choledochal cyst in a patient with pancreas divisum: case report and review of the literature. Case Rep Gastroenterol. 2007 Oct 02;1(1):90-5. doi: 10.1159/000108636. PMID: 21487552; PMCID: PMC3073794.
Copy Download .nbib Format: NLM
Current state of surgical management of pancreatic cancer.

Cancers

Hackert T, Büchler MW, Werner J.
PMID: 24212660
Cancers (Basel). 2011 Mar 10;3(1):1253-73. doi: 10.3390/cancers3011253.

Pancreatic cancer is still associated with a poor prognosis and remains-as the fourth leading cause of cancer related mortality-a therapeutic challenge. Overall long-term survival is about 1-5%, and in only 10-20% of pancreatic cancer patients is potentially curative surgery...

Cite
Hackert T, Büchler MW, Werner J. Current state of surgical management of pancreatic cancer. Cancers (Basel). 2011;3(1):1253-73doi: 10.3390/cancers3011253.
Hackert, T., Büchler, M. W., & Werner, J. (2011). Current state of surgical management of pancreatic cancer. Cancers, 3(1), 1253-73. https://doi.org/10.3390/cancers3011253
Hackert, Thilo, et al. "Current state of surgical management of pancreatic cancer." Cancers vol. 3,1 (2011): 1253-73. doi: https://doi.org/10.3390/cancers3011253
Hackert T, Büchler MW, Werner J. Current state of surgical management of pancreatic cancer. Cancers (Basel). 2011 Mar 10;3(1):1253-73. doi: 10.3390/cancers3011253. PMID: 24212660; PMCID: PMC3756412.
Copy Download .nbib Format: NLM
The Pancreatic Cancer-Initiating Cell Marker CD44v6 Affects Transcription, Translation, and Signaling: Consequences for Exosome Composition and Delivery.

Journal of oncology

Sun H, Rana S, Wang Z, Zhao K, Schnölzer M, Provaznik J, Hackert T, Lv Q, Zöller M.
PMID: 31485223
J Oncol. 2019 Aug 07;2019:3516973. doi: 10.1155/2019/3516973. eCollection 2019.

Pancreatic cancer-initiating cells (PaCIC) express CD44v6 and Tspan8. A knockdown (kd) of these markers hinders the metastatic capacity, which can be rescued, if the cells are exposed to CIC-exosomes (TEX). Additional evidence that CD44v6 regulates Tspan8 expression prompted us...

Cite
Sun H, Rana S, Wang Z, et al. The Pancreatic Cancer-Initiating Cell Marker CD44v6 Affects Transcription, Translation, and Signaling: Consequences for Exosome Composition and Delivery. J Oncol. 2019;2019:3516973doi: 10.1155/2019/3516973.
Sun, H., Rana, S., Wang, Z., Zhao, K., Schnölzer, M., Provaznik, J., Hackert, T., Lv, Q., & Zöller, M. (2019). The Pancreatic Cancer-Initiating Cell Marker CD44v6 Affects Transcription, Translation, and Signaling: Consequences for Exosome Composition and Delivery. Journal of oncology, 20193516973. https://doi.org/10.1155/2019/3516973
Sun, Hanxue, et al. "The Pancreatic Cancer-Initiating Cell Marker CD44v6 Affects Transcription, Translation, and Signaling: Consequences for Exosome Composition and Delivery." Journal of oncology vol. 2019 (2019): 3516973. doi: https://doi.org/10.1155/2019/3516973
Sun H, Rana S, Wang Z, Zhao K, Schnölzer M, Provaznik J, Hackert T, Lv Q, Zöller M. The Pancreatic Cancer-Initiating Cell Marker CD44v6 Affects Transcription, Translation, and Signaling: Consequences for Exosome Composition and Delivery. J Oncol. 2019 Aug 07;2019:3516973. doi: 10.1155/2019/3516973. eCollection 2019. PMID: 31485223; PMCID: PMC6702834.
Copy Download .nbib Format: NLM
Overcoming chemoresistance in pancreatic cancer cells: role of the bitter taste receptor T2R10.

Journal of Cancer

Stern L, Giese N, Hackert T, Strobel O, Schirmacher P, Felix K, Gaida MM.
PMID: 29556329
J Cancer. 2018 Feb 01;9(4):711-725. doi: 10.7150/jca.21803. eCollection 2018.

Bitter taste receptors (T2Rs) are G-protein coupled transmembrane proteins initially identified in the gustatory system as sensors for the taste of bitter. Recent evidence on expression of these receptors outside gustatory tissues suggested alternative functions, and there is growing...

Cite
Stern L, Giese N, Hackert T, et al. Overcoming chemoresistance in pancreatic cancer cells: role of the bitter taste receptor T2R10. J Cancer. 2018;9(4):711-725doi: 10.7150/jca.21803.
Stern, L., Giese, N., Hackert, T., Strobel, O., Schirmacher, P., Felix, K., & Gaida, M. M. (2018). Overcoming chemoresistance in pancreatic cancer cells: role of the bitter taste receptor T2R10. Journal of Cancer, 9(4), 711-725. https://doi.org/10.7150/jca.21803
Stern, Louisa, et al. "Overcoming chemoresistance in pancreatic cancer cells: role of the bitter taste receptor T2R10." Journal of Cancer vol. 9,4 (2018): 711-725. doi: https://doi.org/10.7150/jca.21803
Stern L, Giese N, Hackert T, Strobel O, Schirmacher P, Felix K, Gaida MM. Overcoming chemoresistance in pancreatic cancer cells: role of the bitter taste receptor T2R10. J Cancer. 2018 Feb 01;9(4):711-725. doi: 10.7150/jca.21803. eCollection 2018. PMID: 29556329; PMCID: PMC5858493.
Copy Download .nbib Format: NLM
Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma.

Oncoimmunology

Poschke I, Faryna M, Bergmann F, Flossdorf M, Lauenstein C, Hermes J, Hinz U, Hank T, Ehrenberg R, Volkmar M, Loewer M, Glimm H, Hackert T, Sprick MR, Höfer T, Trumpp A, Halama N, Hassel JC, Strobel O, Büchler M, Sahin U, Offringa R.
PMID: 28123878
Oncoimmunology. 2016 Oct 07;5(12):e1240859. doi: 10.1080/2162402X.2016.1240859. eCollection 2016.

PURPOSE: The devastating prognosis of patients with resectable pancreatic ductal adenocarcinoma (PDA) presents an urgent need for the development of therapeutic strategies targeting disseminated tumor cells. Until now, T-cell therapy has been scarcely pursued in PDA, due to the...

Cite
Poschke I, Faryna M, Bergmann F, et al. Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma. Oncoimmunology. 2016;5(12):e1240859doi: 10.1080/2162402X.2016.1240859.
Poschke, I., Faryna, M., Bergmann, F., Flossdorf, M., Lauenstein, C., Hermes, J., Hinz, U., Hank, T., Ehrenberg, R., Volkmar, M., Loewer, M., Glimm, H., Hackert, T., Sprick, M. R., Höfer, T., Trumpp, A., Halama, N., Hassel, J. C., Strobel, O., Büchler, M., Sahin, U., & Offringa, R. (2016). Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma. Oncoimmunology, 5(12), e1240859. https://doi.org/10.1080/2162402X.2016.1240859
Poschke, Isabel, et al. "Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma." Oncoimmunology vol. 5,12 (2016): e1240859. doi: https://doi.org/10.1080/2162402X.2016.1240859
Poschke I, Faryna M, Bergmann F, Flossdorf M, Lauenstein C, Hermes J, Hinz U, Hank T, Ehrenberg R, Volkmar M, Loewer M, Glimm H, Hackert T, Sprick MR, Höfer T, Trumpp A, Halama N, Hassel JC, Strobel O, Büchler M, Sahin U, Offringa R. Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma. Oncoimmunology. 2016 Oct 07;5(12):e1240859. doi: 10.1080/2162402X.2016.1240859. eCollection 2016. PMID: 28123878; PMCID: PMC5215250.
Copy Download .nbib Format: NLM
Efficacy of vaccination with tumor-exosome loaded dendritic cells combined with cytotoxic drug treatment in pancreatic cancer.

Oncoimmunology

Xiao L, Erb U, Zhao K, Hackert T, Zöller M.
PMID: 28680753
Oncoimmunology. 2017 Apr 20;6(6):e1319044. doi: 10.1080/2162402X.2017.1319044. eCollection 2017.

Pancreatic cancer (PaCa) has a dismal prognosis and adjuvant immunotherapy frequently is of low efficacy due to immunosuppressive features of PaCa and PaCa-stroma. We here explored, whether the efficacy of vaccination with tumor-exosome (TEX)-loaded dendritic cells (DC) can be...

Cite
Xiao L, Erb U, Zhao K, et al. Efficacy of vaccination with tumor-exosome loaded dendritic cells combined with cytotoxic drug treatment in pancreatic cancer. Oncoimmunology. 2017;6(6):e1319044doi: 10.1080/2162402X.2017.1319044.
Xiao, L., Erb, U., Zhao, K., Hackert, T., & Zöller, M. (2017). Efficacy of vaccination with tumor-exosome loaded dendritic cells combined with cytotoxic drug treatment in pancreatic cancer. Oncoimmunology, 6(6), e1319044. https://doi.org/10.1080/2162402X.2017.1319044
Xiao, Li, et al. "Efficacy of vaccination with tumor-exosome loaded dendritic cells combined with cytotoxic drug treatment in pancreatic cancer." Oncoimmunology vol. 6,6 (2017): e1319044. doi: https://doi.org/10.1080/2162402X.2017.1319044
Xiao L, Erb U, Zhao K, Hackert T, Zöller M. Efficacy of vaccination with tumor-exosome loaded dendritic cells combined with cytotoxic drug treatment in pancreatic cancer. Oncoimmunology. 2017 Apr 20;6(6):e1319044. doi: 10.1080/2162402X.2017.1319044. eCollection 2017. PMID: 28680753; PMCID: PMC5486185.
Copy Download .nbib Format: NLM
Response to the Comment on "Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer".

Annals of surgery

Hackert T, Büchler MW.
PMID: 33914457
Ann Surg. 2021 Dec 01;274(6):e899-e900. doi: 10.1097/SLA.0000000000004872.

No abstract available.

Cite
Hackert T, Büchler MW. Response to the Comment on "Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer". Ann Surg. 2021;274(6):e899-e900doi: 10.1097/SLA.0000000000004872.
Hackert, T., & Büchler, M. W. (2021). Response to the Comment on "Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer". Annals of surgery, 274(6), e899-e900. https://doi.org/10.1097/SLA.0000000000004872
Hackert, Thilo, and Büchler, Markus W. "Response to the Comment on "Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer"." Annals of surgery vol. 274,6 (2021): e899-e900. doi: https://doi.org/10.1097/SLA.0000000000004872
Hackert T, Büchler MW. Response to the Comment on "Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer". Ann Surg. 2021 Dec 01;274(6):e899-e900. doi: 10.1097/SLA.0000000000004872. PMID: 33914457.
Copy Download .nbib Format: NLM
Collagen Organization Does Not Influence T-Cell Distribution in Stroma of Human Pancreatic Cancer.

Cancers

Kamionka EM, Qian B, Gross W, Bergmann F, Hackert T, Beretta CA, Dross N, Ryschich E.
PMID: 34359549
Cancers (Basel). 2021 Jul 21;13(15). doi: 10.3390/cancers13153648.

The dominant intrastromal T-cell infiltration in pancreatic cancer is mainly caused by the contact guidance through the excessive desmoplastic reaction and could represent one of the obstacles to an effective immune response in this tumor type. This study analyzed...

Cite
Kamionka EM, Qian B, Gross W, et al. Collagen Organization Does Not Influence T-Cell Distribution in Stroma of Human Pancreatic Cancer. Cancers (Basel). 2021;13(15)doi: 10.3390/cancers13153648.
Kamionka, E. M., Qian, B., Gross, W., Bergmann, F., Hackert, T., Beretta, C. A., Dross, N., & Ryschich, E. (2021). Collagen Organization Does Not Influence T-Cell Distribution in Stroma of Human Pancreatic Cancer. Cancers, 13(15), . https://doi.org/10.3390/cancers13153648
Kamionka, Eva-Maria, et al. "Collagen Organization Does Not Influence T-Cell Distribution in Stroma of Human Pancreatic Cancer." Cancers vol. 13,15 (2021). doi: https://doi.org/10.3390/cancers13153648
Kamionka EM, Qian B, Gross W, Bergmann F, Hackert T, Beretta CA, Dross N, Ryschich E. Collagen Organization Does Not Influence T-Cell Distribution in Stroma of Human Pancreatic Cancer. Cancers (Basel). 2021 Jul 21;13(15). doi: 10.3390/cancers13153648. PMID: 34359549; PMCID: PMC8344977.
Copy Download .nbib Format: NLM
Multimodality standard of care treatment of resectable and borderline resectable pancreatic cancer.

Hepatobiliary surgery and nutrition

Neoptolemos JP, Ghaneh P, Hackert T.
PMID: 34760983
Hepatobiliary Surg Nutr. 2021 Oct;10(5):714-716. doi: 10.21037/hbsn-21-131.

No abstract available.

Cite
Neoptolemos JP, Ghaneh P, Hackert T. Multimodality standard of care treatment of resectable and borderline resectable pancreatic cancer. Hepatobiliary Surg Nutr. 2021;10(5):714-716doi: 10.21037/hbsn-21-131.
Neoptolemos, J. P., Ghaneh, P., & Hackert, T. (2021). Multimodality standard of care treatment of resectable and borderline resectable pancreatic cancer. Hepatobiliary surgery and nutrition, 10(5), 714-716. https://doi.org/10.21037/hbsn-21-131
Neoptolemos, John P, et al. "Multimodality standard of care treatment of resectable and borderline resectable pancreatic cancer." Hepatobiliary surgery and nutrition vol. 10,5 (2021): 714-716. doi: https://doi.org/10.21037/hbsn-21-131
Neoptolemos JP, Ghaneh P, Hackert T. Multimodality standard of care treatment of resectable and borderline resectable pancreatic cancer. Hepatobiliary Surg Nutr. 2021 Oct;10(5):714-716. doi: 10.21037/hbsn-21-131. PMID: 34760983; PMCID: PMC8527429.
Copy Download .nbib Format: NLM
Risk of the Watch-and-Wait Concept in Surgical Treatment of Intraductal Papillary Mucinous Neoplasm.

JAMA surgery

Tjaden C, Sandini M, Mihaljevic AL, Kaiser J, Khristenko E, Mayer P, Hinz U, Gaida MM, Berchtold C, Diener MK, Schneider M, Mehrabi A, Müller-Stich BP, Strobel O, Hackert T, Büchler MW.
PMID: 34009233
JAMA Surg. 2021 Sep 01;156(9):818-825. doi: 10.1001/jamasurg.2021.0950.

IMPORTANCE: The natural history of intraductal papillary mucinous neoplasms (IPMNs) remains uncertain. The inconsistencies among published guidelines preclude accurate decision-making. The outcomes and potential risks of a conservative watch-and-wait approach vs a surgical approach must be compared.OBJECTIVE: To provide...

Cite
Tjaden C, Sandini M, Mihaljevic AL, et al. Risk of the Watch-and-Wait Concept in Surgical Treatment of Intraductal Papillary Mucinous Neoplasm. JAMA Surg. 2021;156(9):818-825doi: 10.1001/jamasurg.2021.0950.
Tjaden, C., Sandini, M., Mihaljevic, A. L., Kaiser, J., Khristenko, E., Mayer, P., Hinz, U., Gaida, M. M., Berchtold, C., Diener, M. K., Schneider, M., Mehrabi, A., Müller-Stich, B. P., Strobel, O., Hackert, T., & Büchler, M. W. (2021). Risk of the Watch-and-Wait Concept in Surgical Treatment of Intraductal Papillary Mucinous Neoplasm. JAMA surgery, 156(9), 818-825. https://doi.org/10.1001/jamasurg.2021.0950
Tjaden, Christine, et al. "Risk of the Watch-and-Wait Concept in Surgical Treatment of Intraductal Papillary Mucinous Neoplasm." JAMA surgery vol. 156,9 (2021): 818-825. doi: https://doi.org/10.1001/jamasurg.2021.0950
Tjaden C, Sandini M, Mihaljevic AL, Kaiser J, Khristenko E, Mayer P, Hinz U, Gaida MM, Berchtold C, Diener MK, Schneider M, Mehrabi A, Müller-Stich BP, Strobel O, Hackert T, Büchler MW. Risk of the Watch-and-Wait Concept in Surgical Treatment of Intraductal Papillary Mucinous Neoplasm. JAMA Surg. 2021 Sep 01;156(9):818-825. doi: 10.1001/jamasurg.2021.0950. PMID: 34009233; PMCID: PMC8135052.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 139 entries